The clinical usefulness of the measurement of cytokines

被引:76
作者
Bienvenu, J [1 ]
Monneret, G
Fabien, N
Revillard, JP
机构
[1] Ctr Hosp Lyon Sud, Serv Immunol, F-69495 Pierre Benite, France
[2] Jeune Equipe Univ Pathol Cellules Lymphoides, Ctr Hosp Lyon Sud, Pierre Benite, France
[3] Hop Edouard Herriot, Unite Immunopharmacol, Lyon, France
关键词
cytokines; cytokine receptors; bioassays; immunoassays; clinical applications;
D O I
10.1515/CCLM.2000.040
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
The utilization of accurate and sensitive methods for the measurement of cytokines in body fluids is prerequisite for the proper use of these mediators in clinical practice. Many factors contribute to the complexity of cytokine quantitation. Bioassays historically preceded immunoassays, which are now very popular, but there is a need for standardization. Nevertheless, due to the local effects of cytokines, the study of their blood levels is of limited value for an understanding of the pathophysiology of these mediators. This explains the development of alternative approaches to assess the ability of cells to produce cytokines. These include the Enzyme-Linked Immune Spot Assay (ELISPOT), the measurement of cell-associated cytokines by flow cytometry, and the study of cytokine secretion by isolated peripheral blood mononuclear cells or by whole blood test. All these techniques, associated with a local detection of cytokines by immunohistochemistry or in situ hybridization and reverse transcriptase polymerase chain reaction, appear to be complementary tools for a better understanding of the biology of cytokines. Selected examples of possible clinical applications related to infectious diseases, cancer, autoimmune diseases, allergy, transplantation and preclinical evaluation of drugs and biotechnology products are given.
引用
收藏
页码:267 / 285
页数:19
相关论文
共 154 条
  • [81] VARIABLE ESTIMATES OF CYTOKINE LEVELS PRODUCED BY COMMERCIAL ELISA KITS - RESULTS USING INTERNATIONAL CYTOKINE STANDARDS
    LEDUR, A
    FITTING, C
    DAVID, B
    HAMBERGER, C
    CAVAILLON, JM
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 1995, 186 (02) : 171 - 179
  • [82] Legoux P, 1992, Eur Cytokine Netw, V3, P553
  • [83] TUMOR-NECROSIS-FACTOR IN SEPSIS
    LEROUXROELS, G
    OFTNER, F
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 263 (11): : 1494 - 1495
  • [84] Inflammatory cytokines in major surgery: a functional perspective
    Lin, E
    Lowry, SF
    [J]. INTENSIVE CARE MEDICINE, 1999, 25 (03) : 255 - 257
  • [85] LINKERISRAELL M, 1991, J IMMUNOL, V147, P17
  • [86] ROLE OF INTERLEUKIN-10 IN THE B-LYMPHOCYTE HYPERACTIVITY AND AUTOANTIBODY PRODUCTION OF HUMAN SYSTEMIC LUPUS-ERYTHEMATOSUS
    LLORENTE, L
    ZOU, WP
    LEVY, Y
    RICHAUDPATIN, Y
    WIJDENES, J
    ALCOCERVARELA, J
    MORELFOURRIER, B
    BROUET, JC
    ALARCONSEGOVIA, D
    GALANAUD, P
    EMILIE, D
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 181 (03) : 839 - 844
  • [87] CCR5 is characteristic of Th1 lymphocytes
    Loetscher, P
    Uguccioni, M
    Bordoli, L
    Baggiolini, M
    Moser, B
    [J]. NATURE, 1998, 391 (6665) : 344 - 345
  • [88] T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function
    Löhning, M
    Stroehmann, A
    Coyle, AJ
    Grogan, JL
    Lin, S
    Gutierrez-Ramos, JC
    Levinson, D
    Radbruch, A
    Kamradt, T
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (12) : 6930 - 6935
  • [89] Louis E, 1998, CLIN EXP IMMUNOL, V113, P401
  • [90] LUDWIG H, 1991, BLOOD, V77, P2794